First Trust Advisors LP Neu Base Therapeutics, Inc. Transaction History

First Trust Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $239,030 - $347,946	-73,098 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $90,011 - $142,696	19,441 Added 36.23%	73,098 $350,000
Q1 2021 May 14, 2021	BUY	$6.92 - $12.36 $30,648 - $54,742	4,429 Added 9.0%	53,657 $397,000
Q4 2020 Feb 02, 2021	SELL	$6.92 - $9.25 $15,397 - $20,581	-2,225 Reduced 4.32%	49,228 $344,000
Q3 2020 Nov 05, 2020	BUY	$7.25 - $9.71 $373,034 - $499,608	51,453 New	51,453 $391,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.